English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Lysine (K)-specific demethylase 5C ( KDM5C ) plays a significant role in the tumor cell proliferation, invasion, drug resistance and the regulation of tumor-related gene expression. Here, we aimed to investigate its predictive value in patients with cancers received immune checkpoint inhibitors (ICIs). We explored the predictive value of  KDM5C  alterations and the association between  KDM5C  alteration and immune landscape by using published cohort with clinical outcome and sequenced data from online database. The frequency of  KDM5C  alterations was 2.1% across 48045 tumor samples with different cancers from 185 studies.  KDM5C  alterations were correlated with markedly inferior overall survival (OS, 53 vs. 102 months,  P <0.0001) than those without. However, in ICI-treated group, patients with  KDM5C  alterations had a substantially prolonged OS than the wild-type group (not reached vs. 18 months,  P =0.0041). The predictive value of  KDM5C  alterations for ICI treatment outcome was not observed in patients with microsatellite-stable tumors ( P =0.2875). Intriguingly, patients with non-small-cell lung cancer and  KDM5C  alterations receiving ICI had the better progression-free survival than wild type group (13.2 vs. 3.2 months,  P =0.0762). Mechanistically,  KDM5C  altered tumors had dramatically higher TMB level and was associated with significantly higher level of CD8+ T cell infiltration and T effector signature. In conclusion,  KDM5C  alterations was correlated with enhanced tumor immunogenicity and inflamed anti-tumor immunity, thus resulting in better treatment outcome in cancer patients receiving ICIs.

Predictive Value of KDM5C Alterations for Immune Checkpoint Inhibitors Treatment Outcomes in Patients With Cancer